AR059417A1 - Quinolonas sustituidas iii, un metodo para su preparacion y su empleo en la fabricacion de un medicamento para el tratamiento o profilaxis de una infeccion con el citomegalovirus humano (hcmv). - Google Patents
Quinolonas sustituidas iii, un metodo para su preparacion y su empleo en la fabricacion de un medicamento para el tratamiento o profilaxis de una infeccion con el citomegalovirus humano (hcmv).Info
- Publication number
- AR059417A1 AR059417A1 ARP070100546A ARP070100546A AR059417A1 AR 059417 A1 AR059417 A1 AR 059417A1 AR P070100546 A ARP070100546 A AR P070100546A AR P070100546 A ARP070100546 A AR P070100546A AR 059417 A1 AR059417 A1 AR 059417A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydroxy
- formula
- alkyl
- compound
- trifluoromethyl
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 2
- 208000015181 infectious disease Diseases 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 title 1
- -1 monofluoro-methoxy, difluoro-methoxy Chemical group 0.000 abstract 10
- 150000001875 compounds Chemical class 0.000 abstract 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 6
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 4
- 150000002367 halogens Chemical group 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- 241000701022 Cytomegalovirus Species 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Chemical group C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 239000000460 chlorine Chemical group 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 125000004185 ester group Chemical group 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 abstract 1
- 239000011737 fluorine Chemical group 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000007660 quinolones Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Quinolonas sustituidas y procesos para su preparacion y su utilizacion para la produccion de medicamentos ara el tratamiento y/o profilaxis de enfermedades, especialmente para su utilizacion como agentes antivirales, particularmente contra los citomegalovirus. Reivindicacion 1: Compuesto caracterizado porque responde a la formula (1) en la cual R1 representa hidrogeno, fluor, cloro o trifluorometilo, R3 representa halogeno, hidroxi, C1-C4-alcoxi, ciano, trifluorometilo, monofluoro- metoxi, difluoro-metoxi, trifluorometoxi o etinilo, R4 representa C1-C6-alquilo o C3-C8-cicloalquilo, donde alquilo se puede sustituir con entre 1 y 3 sustituyentes, donde los sustituyentes se seleccionan en forma independiente cada uno a partir del grupo que consiste en halogeno, hidroxi, amino, ciano, trifluorometilo, hidroxicarbonilo, aminocarbonilo, C1-C-6-alcoxi, C1-C6-alquilamino, C1-C6-alquilcarbonilo y C1-C6-alcoxicarbonilo, y donde cicloalquilo se puede sustituir con entre 1 y 3 sustituyentes, donde los sustituyentes se seleccionan en forma independiente cada uno a partir del grupo que consiste en halogeno, hidroxi, amino, ciano, trifluorometilo, hidroxicarbonilo, aminocarbonilo, C1-C6-alquilo, C1-C6-alcoxi, C1-C6- alquilamino, C1-C6-alquilcarbonilo y C1-C6-alcoxicarbonilo, o R3 y R4, junto con los átomos a los cuales se encuentran unidos, forman un anillo a través de formula (2)donde* es el sitio de union al átomo de carbono, y es el sitio de union al átomo de nitrogeno, R7 y R8 en forma independiente cada uno representa halogeno, hidroxi, ciano, trifluorometilo, monofluorometoxi, difluorometoxi, tri-fluoro-metoxi, C1-C3-alquilo o C1-C3-alcoxi, y R9 representa hidrogeno, halogeno hidroxi, ciano, trifluorometilo, mono-fluorometoxi, difluorometoxi, trifluorometoxi, C1-C3-alquilo o C1-C3-alcoxi, o R8 representa trifluormetoxi, y R7 y R9 representa hidrogeno, R10 representa un de formula (3) donde *es el sitio de union al átomo de carbono, R2 se encuentra unido en la posicion 3 0 4 y representa hidroxi, hidroxi-carbonilo, aminocarbonilo, C1-C4-alquilo, C1-C4-alcoxicarbonilo, C3-C6-cicloalquilaminocarbonilo u opcionalmente C1-C6-alquilaminocarbonilo sustituido con hidroxi, donde alquilo se sustituye con un sustituyente, donde el sustituyente se selecciona a partir del grupo que consiste en hidroxi, hidroxicarbonilo, aminocarbonilo, C1-C4-alcoxi-carbonilo y 2-oxopirrolidin-1-ilo, R5 y R6 en forma independiente cada uno se encuentran unidos en la posicion 3, 4 o 5 y en forma independiente cada uno representa hidrogeno, hidroxi, metilo o etilo, e Y representa un grupo metileno o un átomo de oxígeno, o una de sus sales, sus solvatos o los solvatos de sus sales. Reivindicacion 4:Un proceso para preparacion de un compuesto de formula (1) de acuerdo con la reivindicacion 1, caracterizado porque comprende (a) hacer reaccionar un compuesto de formula (2)en la cual R1, R2, R4 y R10 tienen los valores definidos en la reivindicacion 1, con un compuesto de formula (3) en la cual R7, R8 y R9 tienen los valores definidos en la reivindicacion 1, o (B) hacer reaccionar un compuesto de formula (4) en la cual R1, R3, R4, R7, R8 y R9 tienen los valores definidos en la reivindicacion 1, con un compuesto de formula R10-H (V) en la cual R10 tiene el significado indicado en la reivindicacion (1) o (C) hidrolizar un compuesto formado mediante el proceso (A) o (B) y que lleva un grupo éster en el radical R10 con una base para formar el ácido correspondiente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006005861A DE102006005861A1 (de) | 2006-02-09 | 2006-02-09 | Substituierte Chinolone III |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR059417A1 true AR059417A1 (es) | 2008-04-09 |
Family
ID=38283107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070100546A AR059417A1 (es) | 2006-02-09 | 2007-02-09 | Quinolonas sustituidas iii, un metodo para su preparacion y su empleo en la fabricacion de un medicamento para el tratamiento o profilaxis de una infeccion con el citomegalovirus humano (hcmv). |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US7977349B2 (es) |
| EP (1) | EP1994020B1 (es) |
| JP (1) | JP5198291B2 (es) |
| KR (1) | KR101400568B1 (es) |
| CN (1) | CN101379055B (es) |
| AR (1) | AR059417A1 (es) |
| AT (1) | ATE513826T1 (es) |
| AU (1) | AU2007214006B2 (es) |
| BR (1) | BRPI0706988A2 (es) |
| CA (1) | CA2637204C (es) |
| CY (1) | CY1111805T1 (es) |
| DE (1) | DE102006005861A1 (es) |
| DK (1) | DK1994020T3 (es) |
| DO (1) | DOP2007000027A (es) |
| ES (1) | ES2366970T3 (es) |
| HK (1) | HK1125372A1 (es) |
| IL (1) | IL192662A (es) |
| MY (1) | MY151590A (es) |
| PE (1) | PE20080113A1 (es) |
| PL (1) | PL1994020T3 (es) |
| PT (1) | PT1994020E (es) |
| RU (1) | RU2433125C2 (es) |
| SI (1) | SI1994020T1 (es) |
| TW (1) | TWI382980B (es) |
| UA (1) | UA94934C2 (es) |
| UY (1) | UY30135A1 (es) |
| WO (1) | WO2007090579A2 (es) |
| ZA (1) | ZA200806355B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR059339A1 (es) * | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| TW200811153A (en) | 2006-06-23 | 2008-03-01 | Japan Tobacco Inc | 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
| DE102011101446A1 (de) * | 2011-05-10 | 2012-11-15 | Aicuris Gmbh & Co. Kg | Herstellung von "Dense Bodies" (DB) |
| US11046683B2 (en) | 2016-12-15 | 2021-06-29 | Ono Pharmaceutical Co., Ltd. | Activator of TREK (TWIK RElated K+ channels) channels |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB932487A (en) | 1960-07-25 | 1963-07-31 | D G Searle & Co | Piperidine derivatives |
| DE3420743A1 (de) | 1984-06-04 | 1985-12-05 | Bayer Ag, 5090 Leverkusen | 7-amino-1-cyclopropyl-6,8-dihalogen-1,4-dihydro-4-oxo-3-chinolincarbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel |
| FI871419A (fi) | 1986-03-31 | 1987-10-01 | Sankyo Co | Kinolin-3-karboxylsyraderivat, deras framstaellning och anvaendning. |
| DE3702393A1 (de) | 1987-01-28 | 1988-08-11 | Bayer Ag | 8-cyano-1-cyclopropyl-1,4-dihydro-4-oxo- 3-chinolincarbonsaeuren, verfahren zu ihrer herstellung und diese enthaltende antibakterielle mittel |
| AU618823B2 (en) | 1988-07-20 | 1992-01-09 | Sankyo Company Limited | 4-oxoquinoline-3-carboxylic acid derivatives, their preparation and their use |
| US4959363A (en) | 1989-06-23 | 1990-09-25 | Sterling Drug Inc. | Quinolonecarboxamide compounds, their preparation and use as antivirals. |
| DE4303657A1 (de) | 1993-02-09 | 1994-08-11 | Bayer Ag | Neue Chinolon- und Naphthyridoncarbonsäurederivate |
| FR2713116B1 (fr) | 1993-11-30 | 1996-01-12 | Techmetal Promotion | Dispositif d'alimentation pour le dépôt par simple gravité d'un matériau granuleux sur la surface d'un métal liquide coulé en continu. |
| KR960004339A (ko) | 1994-07-02 | 1996-02-23 | 임성기 | 신규한 퀴놀린계 화합물 및 그 의 제조방법 |
| ATE239477T1 (de) | 1995-08-02 | 2003-05-15 | Darwin Discovery Ltd | Chinolone und deren therapeutische verwendung |
| CA2225555A1 (en) | 1995-08-02 | 1997-02-13 | Chiroscience Limited | Quinolones and their therapeutic use |
| US6248739B1 (en) * | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | Quinolinecarboxamides as antiviral agents |
| DE19937024A1 (de) | 1999-08-05 | 2001-02-08 | Bayer Ag | Verwendung von Acylsulfonamido substituierten Polymethin-Farbstoffen als Fluoreszenz-Farbstoffe und/oder Marker |
| US6525049B2 (en) * | 2000-07-05 | 2003-02-25 | Pharmacia & Upjohn Company | Pyrroloquinolones as antiviral agents |
| EP1305048A2 (en) | 2000-08-01 | 2003-05-02 | Wockhardt Limited | Inhibitors of cellular efflux pumps of microbes |
| GB0023918D0 (en) | 2000-09-29 | 2000-11-15 | King S College London | Antiparasitic compounds |
| US6964966B2 (en) * | 2001-04-25 | 2005-11-15 | Wockhardt Limited | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments |
| AR037097A1 (es) | 2001-10-05 | 2004-10-20 | Novartis Ag | Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento |
| JP2005511743A (ja) | 2001-12-13 | 2005-04-28 | ウォックハート・リミテッド | 新世代の三重標的化したキラルな広域スペクトラム抗菌性の７位置換ピペリジノ−キノロンカルボン酸誘導体、その調製方法、組成物、および医薬としての使用 |
| BRPI0409105A (pt) | 2003-04-07 | 2006-04-25 | Cylene Pharmaceuticals Inc | análogos de quinobenzoxazina substituìdos |
| WO2005049602A1 (en) * | 2003-11-18 | 2005-06-02 | Warner-Lambert Company Llc | Quinolone antibacterial agents |
| DE102004035203A1 (de) | 2004-07-21 | 2006-02-16 | Bayer Healthcare Ag | Substituierte Chinolone |
| DE102005030524A1 (de) | 2005-06-30 | 2007-01-18 | Aicuris Gmbh & Co. Kg | Substituierte Chinolone II |
-
2006
- 2006-02-09 DE DE102006005861A patent/DE102006005861A1/de not_active Ceased
-
2007
- 2007-01-23 MY MYPI20070105 patent/MY151590A/en unknown
- 2007-02-02 JP JP2008553660A patent/JP5198291B2/ja not_active Expired - Fee Related
- 2007-02-02 KR KR1020087021888A patent/KR101400568B1/ko active IP Right Grant
- 2007-02-02 ZA ZA200806355A patent/ZA200806355B/xx unknown
- 2007-02-02 EP EP07711438A patent/EP1994020B1/de active Active
- 2007-02-02 BR BRPI0706988-0A patent/BRPI0706988A2/pt active Search and Examination
- 2007-02-02 CA CA2637204A patent/CA2637204C/en not_active Expired - Fee Related
- 2007-02-02 RU RU2008136079/04A patent/RU2433125C2/ru not_active IP Right Cessation
- 2007-02-02 PT PT07711438T patent/PT1994020E/pt unknown
- 2007-02-02 AT AT07711438T patent/ATE513826T1/de active
- 2007-02-02 SI SI200730702T patent/SI1994020T1/sl unknown
- 2007-02-02 PL PL07711438T patent/PL1994020T3/pl unknown
- 2007-02-02 AU AU2007214006A patent/AU2007214006B2/en not_active Ceased
- 2007-02-02 UA UAA200810891A patent/UA94934C2/uk unknown
- 2007-02-02 ES ES07711438T patent/ES2366970T3/es active Active
- 2007-02-02 WO PCT/EP2007/000923 patent/WO2007090579A2/de active Application Filing
- 2007-02-02 CN CN2007800049872A patent/CN101379055B/zh not_active Expired - Fee Related
- 2007-02-02 DK DK07711438.7T patent/DK1994020T3/da active
- 2007-02-06 DO DO2007000027A patent/DOP2007000027A/es unknown
- 2007-02-07 UY UY30135A patent/UY30135A1/es not_active Application Discontinuation
- 2007-02-08 TW TW096104540A patent/TWI382980B/zh not_active IP Right Cessation
- 2007-02-08 PE PE2007000136A patent/PE20080113A1/es active IP Right Grant
- 2007-02-09 AR ARP070100546A patent/AR059417A1/es unknown
-
2008
- 2008-07-07 IL IL192662A patent/IL192662A/en not_active IP Right Cessation
- 2008-08-08 US US12/188,940 patent/US7977349B2/en not_active Expired - Fee Related
-
2009
- 2009-05-05 HK HK09104157.2A patent/HK1125372A1/xx not_active IP Right Cessation
-
2011
- 2011-08-31 CY CY20111100842T patent/CY1111805T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502866A1 (en) | Fungicidal heterocyclic carboxamides | |
| PH12017500111A1 (en) | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase | |
| MX2019012942A (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak. | |
| TN2016000581A1 (en) | Heteroaryl compounds useful as inhibitors of sumo activating enzyme | |
| PH12015500457A1 (en) | Alkoxy pyrazoles as soluble guanylate cyclase activators | |
| NO20063748L (no) | Kinolinderivater og anvendelse derav som mykobakterielle inhibitorer | |
| PE20150774A1 (es) | Aminoquinolinas como inhibidores de cinasa | |
| MY176278A (en) | Process for producing diazabicyclooctane derivative and intermediate thereof | |
| MX2018001204A (es) | Metodo para preparar derivados de acido 3-(2-anilino-1-ciclohexil- 1h-bencimidazol-5-il)propanoico sustituido. | |
| TNSN08444A1 (en) | Bicyclic derivatives as cetp inhibitors | |
| EA201792072A3 (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения | |
| MX2011009146A (es) | Sales de adicion de aminas que contienen grupos hidroxilo y/o carboxilicos con derivados de acido aminonicotinico como inhibidores de dhodh. | |
| CY1116168T1 (el) | Συγκρυσταλλοι και αλατα αναστολεων toy ccr3 | |
| IN2014DN07082A (es) | ||
| MX2016007056A (es) | Metodos para preparar compuestos de benzoquinolina. | |
| MX2017016370A (es) | Derivados de 4-bencil y 4-benzoil piperidina sustituidos. | |
| MX2017003238A (es) | Metodo para preparar 2'-o-fucosil-lactosa. | |
| AR059417A1 (es) | Quinolonas sustituidas iii, un metodo para su preparacion y su empleo en la fabricacion de un medicamento para el tratamiento o profilaxis de una infeccion con el citomegalovirus humano (hcmv). | |
| PE20120689A1 (es) | Derivados de 5-fluoro-2-oxopirimidina-1(2h)-carboxilato | |
| PH12019500497A1 (en) | Heteroaryl carboxamide compounds as inhibitors of ripk2 | |
| AR070485A1 (es) | Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica | |
| IN2014CN03854A (es) | ||
| MX2021003945A (es) | Compuestos de indolinona para uso como inhibidores de map4k1. | |
| AR036187A1 (es) | Un proceso para la preparacion de perindopril, compuestos analogos y sus sales, compuesto intermediario 2,5-dioxo-oxazolidina y proceso para preparar un intermediario | |
| JP2010536713A5 (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |